Definium Therapeutics, Inc. (DFTX) Stock Profile — Insider Trades & Financials

Net Income-$50.4M

EPS$-2.06

Market Cap$2.1B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Robert Barrow

CEO & Executive Director

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.

Employees: 57
Headquarters: NEW YORK, NY, United States
Website: www.mindmed.co

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

-15.18%

ROA?

-11.46%

D/E Ratio?

0.32

📊

Profitability Ratios

Current Ratio?

6.29

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 18, 2026 (in 102 days)

Annual Report (10-K) — Based on filing pattern

Jul 18, 2026

Predicted10-K

Feb 26, 2026

10-KQ4 20257d after period end

Nov 6, 2025

10-QQ3 20256d after period end

Jul 31, 2025

10-QQ2 20257d after period end

May 8, 2025

10-QQ1 202515d after period end

Mar 6, 2025

10-KQ4 202414d after period end

Nov 7, 2024

10-QQ3 202410d after period end

Aug 13, 2024

10-QQ2 202420d after period end

May 8, 2024

10-QQ1 202415d after period end

Loading company sections...

Definium Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness